Urine-Based Molecular Testing Service

Notice Information

Get alerts for notices like these

Notice Title

Urine-Based Molecular Testing Service

Notice Description

Contract for a Urine-Based Molecular Testing Service

Lot Information

Lot 1

UHNM requires a urine-based molecular testing service from 1 October 2026 to 31 March 2027 to support triage of eligible patients on the non-visible haematuria pathway.

The service must provide a safe, non-invasive alternative to routine diagnostic cystoscopy for an agreed low-risk cohort, while maintaining clinical oversight, safety-netting and rapid escalation for patients with positive or high-risk results.

Scope:

The service will apply to patients referred to the UHNM non-visible haematuria pathway who meet locally agreed eligibility criteria. The provider must support home urine sample collection where required, sample return logistics, laboratory analysis, secure reporting of results, and operational data provision.

Visible haematuria pathways, confirmed bladder cancer management, and patients requiring cystoscopy for other clinical indications are excluded from scope unless otherwise agreed.

Core provider responsibilities:

The supplier must provide clear patient instructions, sample kits and return arrangements where applicable; maintain robust sample identification and chain-of-custody; undertake analysis against the defined bladder cancer-associated molecular panel; apply documented quality controls; manage rejected or insufficient samples promptly; and return results in a format that enables UHNM clinicians to categorise patients as negative/low-risk or positive/high-risk for onward pathway action.

Minimum service levels:

Results should be available to UHNM within 7 calendar days of sample receipt, with at least 90% compliance.

Kits should be issued within 2 working days of eligibility confirmation where applicable. Non-conforming samples must be notified to UHNM within 1 working day, with clear re-collection instructions. Results must be returned through an agreed secure channel and be suitable for recording in the patient record.

Clinical governance and safety:

The service must operate within agreed UHNM clinical decision rules, including eligibility criteria, exclusions, result interpretation, escalation routes and safety-netting for negative results.

Reporting requirements:

The provider and UHNM pathway team must support collection of referral date, eligibility decision date, kit dispatch date, sample receipt date, result date/time, result category, clinical action date and final pathway outcome. A monthly KPI dashboard and quarterly clinical governance pack must be available to monitor turnaround times, sample rejection, result-to-action time, activity delivered, cystoscopy avoidance, patient experience, equity of access and pathway safety.

Implementation expectations:

Mobilisation should be completed within 4 weeks, including confirmation of eligibility criteria, clinical decision rules, reporting routes, patient materials, logistics and baseline data.

A 3-month pilot evaluation should assess operational performance, safety signals, patient experience and cystoscopy avoidance, followed by business-as-usual delivery from month 4 where agreed. A full review should determine clinical effectiveness, capacity release, safety, and value for money.

Procurement outcome sought:

UHNM is seeking a provider capable of delivering a reliable, governed, auditable and patient-centred molecular urine testing service that reduces unnecessary cystoscopy for eligible non-visible haematuria patients, releases urology capacity, improves patient experience, and maintains timely escalation for patients requiring further diagnostic assessment.

The contract duration is from 1 October 2026 to 31 March 2027.

Notice Details

Get alerts for notices like these

Publication & Lifecycle

Open Contracting ID: ocds-h6vhtk-06df03
Publication Source: Find A Tender Service
Latest Notice: https://www.find-tender.service.gov.uk/Notice/075257-2026
Current Stage: Planning
All Stages: Planning

Procurement Classification

Notice Type: Planning Notice
Procurement Type: Standard
Procurement Category: Services
Procurement Method: Not Specified
Procurement Method Details: Not specified
Tender Suitability: Not specified
Awardee Scale: Not specified

Common Procurement Vocabulary (CPV)

CPV Divisions: 85 - Health and social work services
CPV Codes: 85100000 - Health services

Notice Value(s)

Tender Value: £90,000 Under £100K
Lots Value: Not specified
Awards Value: Not specified
Contracts Value: Not specified

Notice Dates

Publication Date: 7 Aug 20264 days ago
Submission Deadline: Not specified
Future Notice Date: 6 Aug 2026Expired
Award Date: Not specified
Contract Period: Not specified - Not specified
Recurrence: Not specified

Notice Status

Tender Status: Planned
Lots Status: Planned
Awards Status: Not Specified
Contracts Status: Not Specified

Buyer & Supplier

Get alerts for notices like these

Contracting Authority (Buyer)

Main Buyer: UNIVERSITY HOSPITALS OF NORTH MIDLANDS NHS TRUST
Contact Name: Available with D3 Tenders Premium →
Contact Email: Available with D3 Tenders Premium →
Contact Phone: Available with D3 Tenders Premium →

Buyer Location

Locality: STOKE ON TRENT
Postcode: ST4 6QG
Post Town: Stoke-on-Trent
Country: England
Major Region (ITL 1): TLG West Midlands (England)
Basic Region (ITL 2): TLG2 Shropshire and Staffordshire
Small Region (ITL 3): TLG23 Stoke-on-Trent
Delivery Location: TLG23 Stoke-on-Trent
Local Authority: Stoke-on-Trent
Electoral Ward: Penkhull & Springfields
Westminster Constituency: Stoke-on-Trent Central

Further Information

Notice URLs

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

{
    "tag": [
        "compiled"
    ],
    "id": "ocds-h6vhtk-06df03-2026-08-07T12:17:15+01:00",
    "date": "2026-08-07T12:17:15+01:00",
    "ocid": "ocds-h6vhtk-06df03",
    "description": "This is a Provider Selection Regime (PSR) intended approach notice. The awarding of this contract is subject to the Health Care Services (Provider Selection Regime) Regulations 2023. For the avoidance of doubt, the provisions of both the Public Contracts Regulations 2015 and the Procurement Act 2023 do not apply to this award. <br/><br/>The award decision makers for this procurement are; Directorate Manager (General Surgery Directorate), UHNM Head of Procurement (Medical), Deputy Director of Procurement and the Director of Finance<br/><br/>The intention is to award a contract using the Most Suitable Provider process.",
    "initiationType": "tender",
    "tender": {
        "id": "MED9962",
        "legalBasis": {
            "id": "32014L0024",
            "scheme": "CELEX"
        },
        "title": "Urine-Based Molecular Testing Service",
        "status": "planned",
        "classification": {
            "scheme": "CPV",
            "id": "85100000",
            "description": "Health services"
        },
        "mainProcurementCategory": "services",
        "description": "Contract for a Urine-Based Molecular Testing Service",
        "value": {
            "amount": 90000,
            "currency": "GBP"
        },
        "lots": [
            {
                "id": "1",
                "description": "UHNM requires a urine-based molecular testing service from 1 October 2026 to 31 March 2027 to support triage of eligible patients on the non-visible haematuria pathway.<br/><br/>The service must provide a safe, non-invasive alternative to routine diagnostic cystoscopy for an agreed low-risk cohort, while maintaining clinical oversight, safety-netting and rapid escalation for patients with positive or high-risk results.<br/><br/>Scope: <br/><br/>The service will apply to patients referred to the UHNM non-visible haematuria pathway who meet locally agreed eligibility criteria. The provider must support home urine sample collection where required, sample return logistics, laboratory analysis, secure reporting of results, and operational data provision. <br/><br/>Visible haematuria pathways, confirmed bladder cancer management, and patients requiring cystoscopy for other clinical indications are excluded from scope unless otherwise agreed.<br/><br/>Core provider responsibilities: <br/><br/>The supplier must provide clear patient instructions, sample kits and return arrangements where applicable; maintain robust sample identification and chain-of-custody; undertake analysis against the defined bladder cancer-associated molecular panel; apply documented quality controls; manage rejected or insufficient samples promptly; and return results in a format that enables UHNM clinicians to categorise patients as negative/low-risk or positive/high-risk for onward pathway action.<br/><br/>Minimum service levels: <br/><br/>Results should be available to UHNM within 7 calendar days of sample receipt, with at least 90% compliance. <br/><br/>Kits should be issued within 2 working days of eligibility confirmation where applicable. Non-conforming samples must be notified to UHNM within 1 working day, with clear re-collection instructions. Results must be returned through an agreed secure channel and be suitable for recording in the patient record.<br/><br/>Clinical governance and safety: <br/><br/>The service must operate within agreed UHNM clinical decision rules, including eligibility criteria, exclusions, result interpretation, escalation routes and safety-netting for negative results.<br/><br/>Reporting requirements: <br/><br/>The provider and UHNM pathway team must support collection of referral date, eligibility decision date, kit dispatch date, sample receipt date, result date/time, result category, clinical action date and final pathway outcome. A monthly KPI dashboard and quarterly clinical governance pack must be available to monitor turnaround times, sample rejection, result-to-action time, activity delivered, cystoscopy avoidance, patient experience, equity of access and pathway safety.<br/><br/>Implementation expectations: <br/><br/>Mobilisation should be completed within 4 weeks, including confirmation of eligibility criteria, clinical decision rules, reporting routes, patient materials, logistics and baseline data. <br/><br/>A 3-month pilot evaluation should assess operational performance, safety signals, patient experience and cystoscopy avoidance, followed by business-as-usual delivery from month 4 where agreed. A full review should determine clinical effectiveness, capacity release, safety, and value for money.<br/><br/>Procurement outcome sought:<br/><br/>UHNM is seeking a provider capable of delivering a reliable, governed, auditable and patient-centred molecular urine testing service that reduces unnecessary cystoscopy for eligible non-visible haematuria patients, releases urology capacity, improves patient experience, and maintains timely escalation for patients requiring further diagnostic assessment.<br/><br/>The contract duration is from 1 October 2026 to 31 March 2027.",
                "status": "planned"
            }
        ],
        "items": [
            {
                "id": "1",
                "deliveryAddresses": [
                    {
                        "region": "UKG23"
                    }
                ],
                "relatedLot": "1"
            }
        ],
        "communication": {
            "futureNoticeDate": "2026-08-07T00:00:00+01:00",
            "atypicalToolUrl": "https://atamis-1928.my.site.com/s/Welcome"
        }
    },
    "parties": [
        {
            "id": "GB-FTS-129332",
            "name": "University Hospitals of North Midlands NHS Trust",
            "identifier": {
                "legalName": "University Hospitals of North Midlands NHS Trust"
            },
            "address": {
                "streetAddress": "Royal Stoke University Hospial, Newcastle Road",
                "locality": "Stoke on Trent",
                "region": "UKG",
                "postalCode": "ST4 6QG",
                "countryName": "United Kingdom"
            },
            "contactPoint": {
                "name": "Lisa Buckley",
                "email": "lisa.buckley@uhnm.nhs.uk"
            },
            "roles": [
                "buyer"
            ],
            "details": {
                "url": "https://www.uhnm.nhs.uk/",
                "buyerProfile": "https://www.uhnm.nhs.uk/",
                "classifications": [
                    {
                        "id": "BODY_PUBLIC",
                        "scheme": "TED_CA_TYPE",
                        "description": "Body governed by public law"
                    },
                    {
                        "id": "07",
                        "scheme": "COFOG",
                        "description": "Health"
                    }
                ]
            }
        }
    ],
    "buyer": {
        "id": "GB-FTS-129332",
        "name": "University Hospitals of North Midlands NHS Trust"
    },
    "language": "en"
}